plasminogen
美 [plæz'mɪnədʒən]英 [plæz'mɪnədʒɪn]
- n.纤维蛋白溶酶原；血纤维蛋的溶酶原；前纤维蛋白溶酶；纤维蛋白溶解原
- 网络纤溶酶原；胞浆素原；血纤维蛋白溶酶原
plasminogenplasminogen
纤溶酶原
生理学教学大纲 - 豆丁网 ... 纤维蛋白溶解 fibrinolysis 纤溶酶原(血浆素原) plasminogen 纤溶酶(血浆素) plasmin ...
纤维蛋白溶酶原
即纤维蛋白溶酶原（Plasminogen）转变为纤维蛋白溶酶，再与纤维蛋白（Fibrin）结合，发挥溶栓作用，而其自身不能直接作 …
胞浆素原
胞浆素原（plasminogen）、胶原和甲状腺素运载蛋白（transthyretin），发生纤溶分解时分别产生的血管静止素（angiostatin…
血纤维蛋白溶酶原
人血纤维蛋白溶酶原（Plasminogen）ELISA试剂盒48T/96T大鼠可溶性凋亡相关因子（sFAS/Apo-1）ELISA 试剂盒 生命科学 …
纤维蛋白酶原
...节蛋白(Thrombomodulin TM) 血浆纤维蛋白酶原(Plasminogen) 抗凝血酶III(ATIII) a2-抗纤溶酶(a-2-Antiplastin) 蛋白C(PC) 纤 …
溶酉每原
...血酉每原转化成凝血酉每的时间延长，并活化血纤维蛋白溶酉每原(plasminogen)，形成血纤维蛋白溶酉每(plasmin)，而间接 …
血纤维蛋白溶脢原
血纤维蛋白溶脢是「血纤维蛋白溶脢原」（plasminogen）的片段，具有五个三环（kringle loop）结构。要活化血纤维蛋白溶脢…
1
Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
结论：糖尿病肾病患者存在血浆纤溶酶原激活物及其抑制物系统失衡。
2
abstract: Objective To investigate the plasminogen activator inhibitor changes in patients with diabetic nephropathy.
目的：探讨糖尿病肾病患者血浆纤溶酶原激活物抑制物的变化。
3
Recombinant tissue-type plasminogen activator (r-TPA) was also used when clinically indicated.
临床上有指征时也可应用重组组织型纤溶酶原激活剂。
4
Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review.
急性缺血性卒中患应用重组组织纤溶酶原激活剂治疗的效用成本：一项系统性回顾
5
The abnormal activity of tissue-type plasminogen activator(t-PA) is the most risk factor of prethrombotic state of cardiovascular diseases.
组织型纤溶酶原激活物（tPA）活性异常是心血管疾病血栓前状态的最危险因素。
6
Plasminogen has been immobilized onto a segmented polyurethane containing amino groups, using glutaraldehyde as coupling agent.
纤溶酶原已被固定在一个分割的含氨基酸组，用偶联剂戊二醛聚氨酯。
7
abstract: Objective: To discuss the clinical value of detecting blood plasminogen activator and inhibitor in cancer patients.
目的：探讨恶性肿瘤患者血液纤溶酶原激活剂与抑制剂检测的临床应用价值。
8
THE EXPRESSION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR IN ORAL SQUAMOUS CELL CARCINOMA.
尿激酶受体在口腔鳞癌中的表达。
9
HMGB1 plays roles in activation of plasminogen and matrix metalloproteases, reorganization of cytoskeleton.
HMGB1与纤维蛋白酶原、基质金属蛋白酶的活化、细胞骨架重组等有关。
10
A drug called tissue plasminogen activator -- tPA -- dissolves clots and restores blood flow.
而一种称为组织纤维蛋白溶酶原激活物（tPA）的药物可以溶解血块，并恢复血液流通。
11
The high-phenol group also experienced a greater drop in the activity of another clot promoter, plasminogen activator inhibitor-1.
高酚早餐组另一血栓促进因子——纤维蛋白溶酶原活化抑制因子-1的活性也呈现显著降低。
12
Reteplase is a part of human tissue-type plasminogen. It is expressed in Escherichia Coli cells.
瑞替普酶是人类组织型纤溶酶原激活物的一部份，在大肠杆菌中合成。
13
Plasminogen activator inhibitor-1(PAI-1)is the main regulator of the fibrinolytic system.
血浆纤溶酶原激活物抑制剂（PAI）-1是纤溶系统的主要调控因子。
14
Plasminogen activator inhibitor-1 (PAI-1) is a single strand glycoprotein, which can inhibit plasminogen activation.
纤溶酶原激活物抑制剂1（PAI-1）是一种单链糖蛋白，起抑制纤溶活性的作用。
15
Because of extensive purpura fulminans with skin necrosis recombinant tissue plasminogen activator (rt-PA) was used.
由于广泛的暴发性紫癜皮肤坏死与重组组织型纤溶酶原激活剂（酶原激活剂）的使用。
16
NIHSS scores were determined before tissue plasminogen activator bolus and at 60 and 120 minutes in both data sets.
在两个试验中，在组织纤维蛋白溶酶原激活剂使用前，都先用NIHSS评分。
17
Objective: To study the risk factor of Triglyceride and Plasminogen Activity on abnormal in patients with Cerbral Infarction.
前言：目的：探讨脑梗塞患者血高甘油三酯与纤溶系统异常的危险因素。
18
Expression and its significance of urokinase-type plasminogen activator system in a nasopharyngeal carcinoma cell line and two sub-lines
尿激酶型纤溶酶原激活剂系统在鼻咽癌细胞系及其两个克隆株中的表达和意义
19
Study of Activity of Plasminogen Activator and Plasminogen Activator Inhibitor in Experimental Diabetic Rats with Cerebral Ischemia
实验性糖尿病大鼠脑缺血纤溶酶原激活物和纤溶酶原激活物抑制剂活性测定
20
Effect of tissue-typed plasminogen activator on the adhesion of platelets on the surface of biomaterials
组织型纤溶酶原激活因子对生物材料表面血小板黏附的影响
21
Effects of Chemical Modification on the Fibrinolytic Activity and Half-Life of Recombinant Tissue-Type Plasminogen Activator
化学修饰对组织型纤溶酶原激活剂的纤溶活性和体内半衰期的影响
22
Dynamic Changes and Significance of Plasma Urokinase-Type Plasminogen Activator and its Receptor in Rats after Pulmonary Thromboembolism
肺血栓栓塞症大鼠血浆尿激酶型纤溶酶原激活物及其受体的动态变化及其意义
23
Construction and Expression of a Recombinant Antibody-targeted Plasminogen Activator
一种导向性溶栓剂的基因构建及其在大肠杆菌中的表达
24
Polymorphism of plasminogen activator inhibitor-1 gene in the children of elderly patients with type 2 diabetes mellitus
老年2型糖尿病患者子女纤溶酶原激活物抑制物1基因的多态性
25
Intravenous thrombolysis therapies in acute myocardial infarction with the reconstructive tissue plasminogen activator in prehospital care
急性心肌梗死院前应用重组组织型纤溶酶原激活剂溶栓研究
26
Expression of urokinase-type plasminogen activator receptor and its significance in laryngeal squamous cell carcinoma
尿激酶型纤溶酶原激活剂受体在喉鳞癌中的表达及意义
27
The relation between the expression of urokinase-type plasminogen activator receptor and clinical pathologic grade in human brain glioma
人脑胶质瘤中尿激酶型纤溶酶原激活物受体的表达与临床病理分级的关系
28
Clinical Thrombolytic Trial of A New Type of Tissue-Plasminogen Activator in Patients with Acute Myocardial Infarction
一种新的人组织纤溶酶原激活剂对急性心肌梗死的溶栓效果
29
Study on the Expression of Urokinase-type Plasminogen Activator Receptor in Thrombotic Patients and its Clinical Implications
尿激酶受体在血栓性疾病中的表达及临床意义
30
Expression of urokinase-type plasminogen activator and its receptor protein in synovial tissues from osteoarthritis
骨关节炎滑膜中尿激酶型纤溶酶原激活物及其受体蛋白的表达